Related Experiment Videos
Cancer chemoprevention agent development strategies for genistein
V E Steele1, M A Pereira, C C Sigman
1Chemoprevention Branch, National Cancer Institute, Bethesda, MD 20892.
Abstract:
Cancer chemoprevention refers to the reduction of cancer incidence by administration of agents or drugs that inhibit, reverse or retard the cancer process. Genistein has demonstrated a wide variety of biological activities that make it a good candidate for a chemopreventive agent. Many agents, such as genistein, are currently being tested with the goal of developing safe and effective chemopreventive drugs for human use. Genistein was investigated as a potential chemopreventive agent in an azoxymethane-induced colon carcinogenesis model. Genistein was tested for its ability to inhibit aberrant colon crypts in the colon of F344 rats that had been treated with azoxymethane. Genistein was administered in the diet from 1 wk before the carcinogen to 4 wk after the first carcinogen dose for a total of 5 wk. At both doses, 75 and 150 mg/kg, the mean number of foci per colon was significantly reduced. Further development of this agent includes demonstration of the preventive efficacy in an in vivo tumorigenesis model, followed by preclinical pharmacology and toxicology testing. Phase 1, 2 and 3 clinical chemoprevention trials would be then performed to determine pharmacokinetics, safe doses, and effectiveness for New Drug Approval.
Insights
Genistein, a potential cancer chemopreventive agent, significantly reduced aberrant colon crypts in a rat model. Further studies are needed to confirm its efficacy and safety for human use.
Area of Science:
- Oncology
- Chemoprevention Research
- Molecular Biology
Background:
- Cancer chemoprevention aims to reduce cancer incidence using agents that inhibit or reverse cancer progression.
- Genistein exhibits diverse biological activities, positioning it as a promising chemopreventive candidate.
- Current research focuses on developing safe and effective chemopreventive drugs for human application.
Purpose of the Study:
- To evaluate genistein's efficacy as a chemopreventive agent in an azoxymethane-induced colon carcinogenesis model.
- To determine if genistein can inhibit the formation of aberrant colon crypts in rats.
Main Methods:
- Genistein was administered orally to F344 rats for 5 weeks, starting 1 week before azoxymethane treatment.
- Two doses of genistein (75 and 150 mg/kg) were tested.
- The number of aberrant colon crypt foci was quantified to assess inhibition.
Main Results:
- Both doses of genistein significantly reduced the mean number of aberrant colon crypt foci per colon.
- Genistein demonstrated dose-dependent inhibition of colon carcinogenesis markers.
Conclusions:
- Genistein shows potential as a chemopreventive agent against colon cancer.
- Further in vivo and preclinical studies, followed by clinical trials, are warranted to establish genistein's therapeutic value.